NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $8.70 +0.27 (+3.20%) Closing price 04:00 PM EasternExtended Trading$8.68 -0.02 (-0.22%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCRX alerts:Sign Up Key Stats Today's Range$8.43▼$8.7350-Day Range$8.12▼$10.7252-Week Range$6.00▼$11.22Volume5.22 million shsAverage Volume4.81 million shsMarket Capitalization$2.22 billionP/E RatioN/ADividend YieldN/APrice Target$20.40Consensus RatingModerate Buy Company Overview BioCryst Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development. BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older. The company markets ORLADEYO in the United States and in international markets, either directly or through commercial partners. In addition to its commercial operations, BioCryst maintains a development pipeline focused on rare diseases, including investigational therapies for complement-mediated conditions and other disorders. The company was founded in 1986 and is headquartered in Durham, North Carolina. Its leadership team is headed by President and Chief Executive Officer Jon P. Stone.AI Generated. May Contain Errors. Read More BioCryst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreBCRX MarketRank™: BioCryst Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 546th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialBioCryst Pharmaceuticals has a consensus price target of $20.40, representing about 136.2% upside from its current price of $8.64.Amount of Analyst CoverageBioCryst Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($2.25) to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -5.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.85% of the float of BioCryst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 14.44, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 3.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.48 News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BioCryst Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest9 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCRX Stock News HeadlinesBioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs1 hour ago | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15 at 12:02 PM | seekingalpha.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.September 17 at 1:00 AM | Porter & Company (Ad)BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth StorySeptember 15 at 3:54 AM | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by AnalystsSeptember 15 at 2:28 AM | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Sector Perform at Royal Bank Of CanadaSeptember 12, 2026 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 7.3% Following Analyst DowngradeSeptember 12, 2026 | americanbankingnews.comModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It (BCRX)Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.September 6, 2026 | marketbeat.comSee More Headlines BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $7.80 on January 1st, 2026. Since then, BCRX stock has increased by 10.7% and is now trading at $8.6350. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The firm's revenue was up 33.6% compared to the same quarter last year. Read the conference call transcript. Who are BioCryst Pharmaceuticals' major shareholders? BioCryst Pharmaceuticals' top institutional shareholders include BlackRock Inc. (9.40%), Jupiter Topco LLC (3.73%), Bank of America Corp DE (1.88%) and Rice Hall James & Associates LLC (0.92%). Insiders that own company stock include Alane P Barnes, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Theresa Heggie, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders and Steve Aselage. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Pfizer (PFE) and PayPal (PYPL). Company Calendar Last Earnings8/05/2026Today9/17/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BCRX's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees435Year Founded1986Price Target and Rating Average Price Target for BioCryst Pharmaceuticals$20.40 High Price Target$32.00 Low Price Target$9.00 Potential Upside/Downside+134.5%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$263.86 million Net Margins-40.90% Pretax Margin-40.53% Return on Equity-86.89% Return on Assets66.37% Debt Debt-to-Equity RatioN/A Current Ratio2.32 Quick Ratio2.29 Sales & Book Value Annual Sales$874.84 million Price / Sales2.54 Cash Flow$1.32 per share Price / Cash Flow6.59 Book Value($0.57) per share Price / Book-15.26Miscellaneous Outstanding Shares255,540,000Free Float245,825,000Market Cap$2.22 billion OptionableOptionable Beta0.57 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:BCRX) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
